Yuliya Lytvyn1, Petter Bjornstad, Nicole Pun, David Z I Cherney. 1. aDivision of Nephrology, Department of Medicine, University Health Network bDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada cDepartment of Pediatric Endocrinology, University of Colorado School of Medicine dBarbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado, USA *Drs Lytvyn, Bjornstad and Pun are the co-first authors of the article.
Abstract
PURPOSE OF REVIEW: Diabetic nephropathy is a long-standing complication of diabetes mellitus and is responsible for more than 40% of end-stage renal disease cases in developed countries. Unfortunately, conventional renin-angiotensin-aldosterone system (RAAS) inhibitor medications only partially protect against the development and progression of diabetic nephropathy. Moreover, RAAS inhibitors have failed as primary prevention therapy in type 1 diabetes. Thus, agents targeting alternative pathogenic mechanisms leading to diabetic nephropathy have been intensively investigated, which is the topic of this review. RECENT FINDINGS: Promising emerging agents have targeted neurohormonal activation (alternative components of the RAAS and neprilysin inhibition), tubuloglomerular feedback mechanisms (sodium glucose cotransporter 2 inhibition and incretin-based therapy) and renal inflammation/fibrosis. SUMMARY: Evidence demonstrating the potential of these agents to protect and prevent progression of diabetic nephropathy is summarized in this review. There are dedicated clinical trials ongoing with these therapies, which have the potential to change the clinical practice.
PURPOSE OF REVIEW: Diabetic nephropathy is a long-standing complication of diabetes mellitus and is responsible for more than 40% of end-stage renal disease cases in developed countries. Unfortunately, conventional renin-angiotensin-aldosterone system (RAAS) inhibitor medications only partially protect against the development and progression of diabetic nephropathy. Moreover, RAAS inhibitors have failed as primary prevention therapy in type 1 diabetes. Thus, agents targeting alternative pathogenic mechanisms leading to diabetic nephropathy have been intensively investigated, which is the topic of this review. RECENT FINDINGS: Promising emerging agents have targeted neurohormonal activation (alternative components of the RAAS and neprilysin inhibition), tubuloglomerular feedback mechanisms (sodium glucose cotransporter 2 inhibition and incretin-based therapy) and renal inflammation/fibrosis. SUMMARY: Evidence demonstrating the potential of these agents to protect and prevent progression of diabetic nephropathy is summarized in this review. There are dedicated clinical trials ongoing with these therapies, which have the potential to change the clinical practice.
Authors: M Carmen Iglesias-de la Cruz; Fuad N Ziyadeh; Motohide Isono; Martine Kouahou; Dong Cheol Han; Raghu Kalluri; Peter Mundel; Sheldon Chen Journal: Kidney Int Date: 2002-09 Impact factor: 10.612
Authors: Bruce A Perkins; David Z I Cherney; Helen Partridge; Nima Soleymanlou; Holly Tschirhart; Bernard Zinman; Nora M Fagan; Stefan Kaspers; Hans-Juergen Woerle; Uli C Broedl; Odd-Erik Johansen Journal: Diabetes Care Date: 2014-03-04 Impact factor: 19.112
Authors: José A Hernández Prada; Anderson J Ferreira; Michael J Katovich; Vinayak Shenoy; Yanfei Qi; Robson A S Santos; Ronald K Castellano; Andrew J Lampkins; Vladimir Gubala; David A Ostrov; Mohan K Raizada Journal: Hypertension Date: 2008-04-07 Impact factor: 10.190
Authors: Volker Vallon; Maria Gerasimova; Michael A Rose; Takahiro Masuda; Joseph Satriano; Eric Mayoux; Hermann Koepsell; Scott C Thomson; Timo Rieg Journal: Am J Physiol Renal Physiol Date: 2013-11-13
Authors: Yagna P R Jarajapu; Ashay D Bhatwadekar; Sergio Caballero; Sugata Hazra; Vinayak Shenoy; Reinhold Medina; David Kent; Alan W Stitt; Catherine Thut; Eva M Finney; Mohan K Raizada; Maria B Grant Journal: Diabetes Date: 2012-12-10 Impact factor: 9.461
Authors: Yuliya Lytvyn; Lucas C Godoy; Rosalie A Scholtes; Daniël H van Raalte; David Z Cherney Journal: Curr Diab Rep Date: 2019-01-23 Impact factor: 4.810
Authors: David León Jiménez; David Z I Cherney; Petter Bjornstad; Luis Castilla-Guerra; José Pablo Miramontes González Journal: Am J Physiol Renal Physiol Date: 2018-08-01
Authors: Yuliya Lytvyn; Petter Bjornstad; Jacob A Udell; Julie A Lovshin; David Z I Cherney Journal: Circulation Date: 2017-10-24 Impact factor: 29.690
Authors: Vikas Srinivasan Sridhar; Jaya Prakash N Ambinathan; Matthias Kretzler; Laura L Pyle; Petter Bjornstad; Sean Eddy; David Z Cherney; Heather N Reich Journal: Am J Physiol Renal Physiol Date: 2019-09-23
Authors: Petter Bjornstad; Edward Nehus; Laure El Ghormli; Fida Bacha; Ingrid M Libman; Siripoom McKay; Steven M Willi; Lori Laffel; Silva Arslanian; Kristen J Nadeau Journal: Am J Kidney Dis Date: 2017-11-20 Impact factor: 8.860
Authors: Annayya R Aroor; Nitin A Das; Andrea J Carpenter; Javad Habibi; Guanghong Jia; Francisco I Ramirez-Perez; Luis Martinez-Lemus; Camila M Manrique-Acevedo; Melvin R Hayden; Cornel Duta; Ravi Nistala; Eric Mayoux; Jaume Padilla; Bysani Chandrasekar; Vincent G DeMarco Journal: Cardiovasc Diabetol Date: 2018-07-30 Impact factor: 9.951